The current financial score of Sunshine Biopharma Inc is 8.17. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 9.44M, representing a year-over-year increase of 0.27%, while its net profit experienced a year-over-year increase of 38.48%.
The current valuation score of Sunshine Biopharma Inc is 9.91. Its current P/E ratio is -2.15, which is -114.24% below the recent high of 0.31 and -23.33% above the recent low of -2.65.
The current earnings forecast score of Sunshine Biopharma Inc is 8.00. The average price target is 1120.00, with a high of 1120.00 and a low of 1120.00.
The current price momentum score of Sunshine Biopharma Inc is 6.16. Currently, the stock price is trading between the resistance level at 4.32 and the support level at 1.81, making it suitable for range-bound swing trading.
The current institutional shareholding score of Sunshine Biopharma Inc is 3.00. The latest institutional shareholding proportion is 5.17%, representing a quarter-over-quarter decrease of 31.56%.
The current risk assessment score of Sunshine Biopharma Inc is 1.24. The company's beta value is 1.36. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.